Comparative Pharmacology
Head-to-head clinical analysis: CANCIDAS versus MYCAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANCIDAS versus MYCAMINE.
CANCIDAS vs MYCAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Caspofungin inhibits the synthesis of β-(1,3)-D-glucan, an essential component of the fungal cell wall, by noncompetitive inhibition of the enzyme β-(1,3)-D-glucan synthase, leading to osmotic instability and cell death.
Micafungin is an echinocandin antifungal that inhibits the synthesis of 1,3-β-D-glucan, an essential component of the fungal cell wall, leading to osmotic instability and cell death.
70 mg IV once, followed by 50 mg IV once daily thereafter.
100 mg IV once daily for invasive candidiasis; 150 mg IV once daily for esophageal candidiasis.
None Documented
None Documented
The terminal elimination half-life is approximately 40–50 hours in adults. A multi-exponential decline is observed; the beta half-life is 9–11 hours, and the gamma (terminal) half-life is 40–50 hours. This supports once-daily dosing after a loading dose.
Terminal elimination half-life is approximately 14.3 hours (range 11–17 hours) in healthy adults. In pediatric patients, half-life is shorter (approximately 10–12 hours). Clinically, steady state is achieved by day 3 with daily dosing.
Renal excretion of unchanged drug is minimal (approximately 1% of dose). The primary route of elimination is biliary/fecal, with about 70% of a radiolabeled dose recovered in feces over 14 days, mostly as metabolites. Urinary excretion accounts for about 10% of total radioactivity, primarily as metabolites.
Primarily excreted unchanged via feces (approximately 28%) and to a lesser extent via urine (approximately 15%). Overall, elimination is primarily non-renal with biliary/fecal excretion as the major route. Less than 1% is excreted as metabolites.
Category C
Category C
Echinocandin Antifungal
Echinocandin Antifungal